Advanced systemic mastocytosis (advSM), including aggressive SM (ASM), SM with an associated hematologic neoplasm (SM-AHN) and mast cell leukemia (MCL), are rare, mostly KIT D816V-driven malignancies with a poor prognosis. KIT D816V-targeting drugs, such as midostaurin or avapritinib, can induce hematologic responses i...
Max Vincent John, Yüksel Filik Schüppler, Nadine Witzeneder et al.· Cells· 0 citations
Genotyping of Transcriptomes is used to elucidate specific KRASG12D-driven pathways in preleukemic Clonal Hematopoiesis and 3 Acute Myeloid Leukemia patient samples and identify a novel quiescent CD83+ KRASG12D progenitor population in AML and demonstrate the therapeutic potential of MRTX1133 in vivo.
Leah Kravets, Ritesh Agarwal, Srinivas Aluri et al.· Journal of Immunology· 0 citations
Preclinical development of LY3410738, an oral, dual IDH1/2 inhibitor with potential to penetrate the blood-brain barrier is presented, which synergized and was well tolerated with standard-of-care regimens such as cytarabine, azacitidine, venetoclax, or midostaurin in IDH1/2-mutated AML PDXs.
Nathan A Brooks, Anna Skwarska, V. Salama et al.· Blood Cancer Discovery· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
